Aspiration First Approach With Penumbra System Shows Favorable Outcomes for Acute Ischemic Stroke

Penumbra Inc., a global healthcare company focused on innovative therapies, has announced results of the company-sponsored PROMISE Study, demonstrating real-world safety and efficacy of the Penumbra System with ACE68 and ACE64 Reperfusion Catheters as frontline treatment in patients with acute ischemic stroke using the ADAPT (A Direct Aspiration First Pass Technique) approach.
 
“ADAPT as a frontline approach demonstrated excellent results—both in revascularization rates and clinical outcomes,” said Peter Schramm, M.D., from the department of Neuroradiology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany. “In addition, the low mortality rate and strong safety profile indicate that stroke revascularization with aspiration is safer and more effective with ACE68 and ACE64 than ever before.”
 
The PROMISE Study was a prospective, single-arm multi-center study that enrolled 204 patients across 20 European centers. Core-lab adjudicated mTICI 2b-3 revascularization was attained in 93.1 percent of patients, with 39.2 percent of patients attaining mTICI 3 revascularization. Clinical independence, measured by modified Rankin Score (mRS) 0-2, was achieved in 61 percent of patients at 90 days. Key secondary safety related endpoints also demonstrated excellent results: All-cause mortality at 90 days was 7.5 percent, symptomatic intracranial hemorrhage (sICH) at 24 hours was 2.9 percent and embolization in new territories (ENT) was 1.5 percent. Median procedure time, as measured as groin puncture to mTICI 2b-3 revascularization, was 31 min [20.0 – 53.0].
 
“We thank the PROMISE investigators for this important contribution to the growing body of global evidence supporting ADAPT as a frontline approach for patients with acute ischemic stroke,” said Adam Elsesser, chairman, CEO and president of Penumbra. “The PROMISE study affirms our belief that the Penumbra System with ACE68 offers a rapid, safe and cost-effective approach for ischemic stroke revascularization.”
 
PROMISE was a company-sponsored, prospective, single-arm, multi-center observational study that aimed to observe the real-life safety and effectiveness of the Penumbra System with ACE68 and ACE64 Reperfusion Catheters in patients with acute ischemic stroke from large vessel occlusion, treated with the ADAPT technique as a frontline approach. The study enrolled 204 patients across 20 European centers. The primary endpoints were revascularization rates as measured by mTICI 2b-3 adjudicated by independent Core Laboratory and clinical independence at 90 days, as measured by modified Rankin Score (mRS) 0-2.

The Penumbra System is a fully integrated system designed specifically for mechanical thrombectomy by aspiration that first received 510(k) clearance by the U.S. Food and Drug Administration in December 2007. The Penumbra System enables physicians to use aspiration, which acts like a minimally invasive “vacuum” inside the artery to remove stroke-causing blood clots from the brain safely and effectively. It is intended for use in the revascularization of patients with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion. The latest generation of the Penumbra System features the ACE Reperfusion Catheters, Hi-Flow Aspiration Tubing, the 3D Revascularization Device and Pump MAX aspiration pump and accessories. Launched in 2016, the ACE68 Reperfusion Catheter offers outstanding trackability and enables even greater aspiration power for clot removal through its large .068-inch lumen. Launched in 2017, the 3D Revascularization Device is a next-generation stroke device, designed and optimized for aspiration with ACE Reperfusion Catheters.
 
Penumbra, Inc., headquartered in Alameda, Calif., is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets medical devices and has a portfolio of products that addresses challenging medical conditions and significant clinical needs. Penumbra sells its products to hospitals and clinics primarily through its direct sales organization in the United States, most of Europe, Canada and Australia, and through distributors in select international markets.